Summary & Overview
HCPCS J9178: Epirubicin HCl Injection, 2 mg
HCPCS Level II code J9178 designates an injection of epirubicin hydrochloride, 2 mg, an antineoplastic agent commonly used in oncology infusion settings. This code is used for billing discrete units of epirubicin when administered parenterally and is relevant to reimbursement, utilization monitoring, and clinical documentation for chemotherapy services nationwide. Nationally, accurate coding of antineoplastic agents affects claims processing, drug cost reporting, and care coordination across payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the code’s clinical context, common sites of service, and the payer landscape. The publication also summarizes benchmarks and policy considerations that affect billing for injectable chemotherapy agents, such as unit reporting and outpatient infusion billing practices. Practical information is provided on common modifiers used with HCPCS Level II drug codes and considerations for claim submission.
This document serves clinicians, billing professionals, and policy analysts seeking a national-level briefing on HCPCS Level II code J9178, how it is used in practice, and what payers typically expect for billing epirubicin injections in outpatient oncology settings.
Billing Code Overview
HCPCS Level II code J9178 represents an injection of epirubicin hydrochloride, dosed at 2 mg per unit. This medication is an anthracycline chemotherapeutic agent used in oncology for systemic antineoplastic therapy.
-
Service type: Intravenous or intramuscular chemotherapy administration (antineoplastic injection)
-
Typical site of service: Outpatient oncology infusion center, hospital outpatient department, or clinic setting where parenteral chemotherapy is administered.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 62-year-old female with newly diagnosed metastatic breast cancer is scheduled to receive intravenous epirubicin as part of a systemic chemotherapy regimen. The oncology clinic verifies baseline labs (CBC, renal and hepatic panel), reviews prior anthracycline exposure and cardiac function (echocardiogram or MUGA with LVEF measurement), obtains informed consent, and confirms central venous access or peripheral IV patency. Pharmacy prepares J9178 (epirubicin HCl, 2 mg vial) under sterile conditions, calculates the patient-specific dose by body surface area, and compounds the infusion. The patient is premedicated as indicated, monitored for infusion-related reactions, and observed post-administration for extravasation, cardiotoxicity signs, and hematologic adverse events. Documentation includes drug name and NDC, amount administered in milligrams, lot number, route, site of service, applicable modifier(s), and the primary ICD-10 diagnosis driving therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug wastage discarded | Used when part of a multi-dose vial is discarded after compounding/administration and wastage must be reported. |
JZ |